LCZ696: A new paradigm for the treatment of heart failure?

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 3, 2015, Pages 435-446

  Minguet, Joan ^a,b   Sutton, Gemma ^a   Ferrero, Carmen ^c   Gomez, Timothy ^a   Bramlage, Peter ^a,b,c  

^a Institute for Research and Medicine Advancement (IRMEDICA)   (Spain)

^b Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Angiotensin receptor blocker; Angiotensin receptor neprilysin inhibitor; Heart failure; Neprilysin; Valsartan

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ANGIOTENSIN RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL; VALSARTAN; 3-(1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-3'-METHYL-2'-(PENTANOYL(2'-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG COMBINATION; TETRAZOLE DERIVATIVE; VALINE;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EFFICACY; HEART FAILURE; HUMAN; IN VITRO STUDY; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SAFETY; PHARMACODYNAMICS; PREVALENCE; PROGNOSIS; REVIEW; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECTS; PHASE 2 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG COMBINATIONS; HEART FAILURE; HUMANS; NEPRILYSIN; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 84921450419     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1000300     Document Type: Review

References (54)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
3. Dunlay SM, Roger VL. Understanding the Epidemic of Heart Failure: past, Present, and Future. Curr Heart Fail Rep 2014;11:404-15
4. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011;8:30-41
5. Roger VL. Epidemiology of heart failure. Circ Res 2013;113:646-59
6. Allen LA, Magid DJ, Gurwitz JH, et al. Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population. Circ Heart Fail 2013;6:635-46
7. Metra M, Lombardi C. Renin-Angiotensin system blockade and worsening renal function in heart failure: an unfinished story. J Am Coll Cardiol 2014;64:1114-16
8. Damman K, Perez AC, Anand IS, et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol 2014;64:1106-13
9. Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 2014;35:1022-32
10. Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2014;11(4):354-65
11. Zouein FA, de Castro Bras LE, da Costa DV, et al. Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol 2013;62:13-21
12. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012;126:65-75
13. Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013;34:1424-31
14. Chamberlain AM, St Sauver JL, Gerber Y, et al. Multimorbidity in heart failure: a community perspective. Am J Med 2015;128(1):38-45
15. Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2012;5:571-8
16. Hamaguchi S, Kinugawa S, Sobirin MA, et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 2012;76:1662-9
17. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35
18. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302
19. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
20. Di Franco A, Sarullo FM, Salerno Y, et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs 2014;14:101-10
21. D'Elia E, Krum H. Mineralcorticoid antagonists in heart failure. Heart Fail Clin 2014;10:559-64
22. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21
23. McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16:817-25
24. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013;10:125-34
25. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013;6:594-605
26. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014;144:41-9
27. Judge P, Haynes R, Landray MJ, et al. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 2014. [Epub ahead of print]
28. Del Ry S, Cabiati M, Lionetti V, et al. Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart. Peptides 2008;29:2208-15
29. Pagel-Langenickel I, Buttgereit J, Bader M, et al. Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J Mol Med (Berl) 2007;85:797-810
30. Cocco G, Jerie P. Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure. Cardiol J 2014. [Epub ahead of print]
31. Flint KM, Allen LA, Pham M, Heidenreich PA. B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes. J Am Heart Assoc 2014;3:e000806
32. Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol 2014;176:630-9
33. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002;106:920-6
34. Tom B, Dendorfer A, de Vries R, et al. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 2002;137:276-84
35. Knecht SE, Dunn SP, Macaulay TE. Angioedema related to Angiotensin inhibitors. J Pharm Pract 2014;27:461-5
36. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008;51:1465-7
37. Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 2013;94:445-8
38. Novartis AG. Media release. Available from: http://www.novartis.com/newsroom/media-releases/en/2014/1852531.shtml [Last accessed October 10, 2014]
39. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004
40. von Lueder TG, Wang BH, Kompa AR, et al. The angiotensin-receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2014. [Epub ahead of print]
41. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-14
42. Novartis AG. Clinical Study. Available from: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=5309 [Last accessed October 4, 2014]
43. Novartis AG. Available from: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=5308 [Last accessed October 10, 2014]
44. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062-73
45. Zois NE, Bartels ED, Hunter I, et al. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol 2014;11:403-12
46. Birkenfeld AL, Adams F, Schroeder C, et al. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension 2011;57:e4-5
47. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582-9
48. Loftus PA, Tan M, Patel G, et al. Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors. Laryngoscope 2014;124(11):2502-7
49. Pare G, Kubo M, Byrd JB, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 2013;23:470-8
50. WHO. Available from: http://www.who.int/mediacentre/factsheets/fs317/en [Last accessed October 10, 2014]
51. Jessup M, Fox KA, Komajda M, et al. PARADIGM-HF - the experts' discussion. N Engl J Med 2014;371:e15
52. Jessup M. Neprilysin inhibition - a novel therapy for heart failure. N Engl J Med 2014;371:1062-4
53. El-Refai M, Hrobowski T, Peterson EL, et al. Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure. J Cardiovasc Med (Hagerstown) 2014. [Epub ahead of print]
54. Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A Biol Sci Med Sci 2001;56:M88-96